Literature DB >> 21997290

The Weiss score and beyond--histopathology for adrenocortical carcinoma.

Mauro Papotti1, Rossella Libè, Eleonora Duregon, Marco Volante, Jerome Bertherat, Frederique Tissier.   

Abstract

The pathological diagnosis of adrenocortical carcinoma (ACC) is still challenging for its rarity and the presence of special variants (pediatric, oncocytic, myxoid, and sarcomatoid). It is based on the recognition at light microscopy of at least three among nine morphological parameters, according to the Weiss scoring system, which has been introduced 27 years ago and nowadays is the most widely employed. Nevertheless, the diagnostic performance of this system is very high but does not reach a sensitivity and specificity of 100%, its diagnostic applicability is potentially low among non-expert pathologists, and a group of borderline cases with only one or two criteria exist of uncertain behavior. Moreover, it is scarcely reproducible in the ACC morphological variants. In fact, specifically for the pure oncocytic neoplasms that seem to have a better prognosis in comparison to the conventional ACCs, a modified system (the Lin-Weiss-Bisceglia) has been proposed. With the aim to simplify the ACC diagnosis, 2 years ago, the "reticulin" diagnostic algorithm has been proposed, based on the observation that the tumoral reticulin framework (highlighted by reticulin silver-based histochemical staining) is consistently disrupted in malignant cases but only in a small subset of benign cases. Following this algorithm, in the presence of reticulin alterations, malignancy is further defined through the identification of at least one of the following parameters: necrosis, high mitotic rate, and venous invasion. As a complement to the morphological approach, some immunohistochemical markers (such as steroidogenic factor 1) have been proposed as diagnostic and prognostic adjuncts but still lack wide clinical validation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21997290     DOI: 10.1007/s12672-011-0088-0

Source DB:  PubMed          Journal:  Horm Cancer        ISSN: 1868-8497            Impact factor:   3.869


  50 in total

1.  High expression of cyclin E and G1 CDK and loss of function of p57KIP2 are involved in proliferation of malignant sporadic adrenocortical tumors.

Authors:  N Bourcigaux; V Gaston; A Logié; X Bertagna; Y Le Bouc; C Gicquel
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

2.  The argument for mitotic rate-based grading for the prognostication of adrenocortical carcinoma.

Authors:  Thomas J Giordano
Journal:  Am J Surg Pathol       Date:  2011-04       Impact factor: 6.394

Review 3.  Adrenocortical carcinosarcoma: a case report and review of the literature.

Authors:  Kotaro Sasaki; Marisa Desimone; Harsha R Rao; George J Huang; Raja R Seethala
Journal:  Diagn Pathol       Date:  2010-08-05       Impact factor: 2.644

4.  Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors.

Authors:  Frédérique Tissier; Catherine Cavard; Lionel Groussin; Karine Perlemoine; Gwladys Fumey; Anne-Marie Hagneré; Fernande René-Corail; Eric Jullian; Christine Gicquel; Xavier Bertagna; Marie-Cécile Vacher-Lavenu; Christine Perret; Jérôme Bertherat
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

5.  Adrenal carcinosarcoma.

Authors:  J W Decorato; H Gruber; M Petti; B S Levowitz
Journal:  J Surg Oncol       Date:  1990-10       Impact factor: 3.454

6.  Transcription factor adrenal 4 binding protein as a marker of adrenocortical malignancy.

Authors:  H Sasano; S Shizawa; T Suzuki; K Takayama; T Fukaya; K Morohashi; H Nagura
Journal:  Hum Pathol       Date:  1995-10       Impact factor: 3.466

7.  Cyclin E correlates with malignancy and adverse prognosis in adrenocortical tumors.

Authors:  Frédérique Tissier; Albert Louvel; Sophie Grabar; Anne-Marie Hagnéré; Jérôme Bertherat; Marie-Cécile Vacher-Lavenu; Bertrand Dousset; Yves Chapuis; Xavier Bertagna; Christine Gicquel
Journal:  Eur J Endocrinol       Date:  2004-06       Impact factor: 6.664

8.  Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity.

Authors:  Rossella Libè; Lionel Groussin; Frédérique Tissier; Caroline Elie; Fernande René-Corail; Amato Fratticci; Eric Jullian; Paolo Beck-Peccoz; Xavier Bertagna; Christine Gicquel; Jérôme Bertherat
Journal:  Clin Cancer Res       Date:  2007-02-01       Impact factor: 12.531

9.  The prognostic value of two different histopathological scoring systems for adrenocortical carcinomas.

Authors:  H P van't Sant; N D Bouvy; G Kazemier; H J Bonjer; W C J Hop; R A Feelders; W W de Herder; R R de Krijger
Journal:  Histopathology       Date:  2007-06-25       Impact factor: 5.087

Review 10.  Adrenocortical cancer: pathophysiology and clinical management.

Authors:  Rossella Libè; Amato Fratticci; Jérôme Bertherat
Journal:  Endocr Relat Cancer       Date:  2007-03       Impact factor: 5.678

View more
  36 in total

Review 1.  Management of adrenal cancer: a 2013 update.

Authors:  M Terzolo; F Daffara; A Ardito; B Zaggia; V Basile; L Ferrari; A Berruti
Journal:  J Endocrinol Invest       Date:  2014-03       Impact factor: 4.256

2.  Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).

Authors:  A Stigliano; I Chiodini; R Giordano; A Faggiano; L Canu; S Della Casa; P Loli; M Luconi; F Mantero; M Terzolo
Journal:  J Endocrinol Invest       Date:  2015-07-14       Impact factor: 4.256

Review 3.  Roles of the pathologist in evaluating surrogate markers for medical therapy in adrenocortical carcinoma.

Authors:  Hironobu Sasano; Fumitoshi Satoh; Yasuhiro Nakamura
Journal:  Endocr Pathol       Date:  2014-12       Impact factor: 3.943

4.  Does Lymphadenectomy Improve Survival in Patients with Adrenocortical Carcinoma? A Population-Based Study.

Authors:  Naris Nilubol; Dhaval Patel; Electron Kebebew
Journal:  World J Surg       Date:  2016-03       Impact factor: 3.352

Review 5.  Adrenocortical carcinoma.

Authors:  Tobias Else; Alex C Kim; Aaron Sabolch; Victoria M Raymond; Asha Kandathil; Elaine M Caoili; Shruti Jolly; Barbra S Miller; Thomas J Giordano; Gary D Hammer
Journal:  Endocr Rev       Date:  2013-12-20       Impact factor: 19.871

Review 6.  Applications of high-resolution magic angle spinning MRS in biomedical studies II-Human diseases.

Authors:  Christopher Dietz; Felix Ehret; Francesco Palmas; Lindsey A Vandergrift; Yanni Jiang; Vanessa Schmitt; Vera Dufner; Piet Habbel; Johannes Nowak; Leo L Cheng
Journal:  NMR Biomed       Date:  2017-09-15       Impact factor: 4.044

7.  P53/Rb inhibition induces metastatic adrenocortical carcinomas in a preclinical transgenic model.

Authors:  M Batisse-Lignier; I Sahut-Barnola; F Tissier; T Dumontet; M Mathieu; C Drelon; J-C Pointud; C Damon-Soubeyrand; G Marceau; J-L Kemeny; J Bertherat; I Tauveron; P Val; A Martinez; A-M Lefrançois-Martinez
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

8.  A Phase II Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Adrenocortical Carcinoma.

Authors:  Marybeth S Hughes; Winifred M Lo; Tatiana Beresnev; Maria Merino; Yvonne Shutack; R Taylor Ripley; Jonathan M Hernandez; Jeremy L Davis
Journal:  J Surg Res       Date:  2018-12       Impact factor: 2.192

Review 9.  Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours.

Authors:  Alfred King-Yin Lam
Journal:  Endocr Pathol       Date:  2017-09       Impact factor: 3.943

Review 10.  Immunohistochemical Biomarkers of Adrenal Cortical Neoplasms.

Authors:  Ozgur Mete; Sylvia L Asa; Thomas J Giordano; Mauro Papotti; Hironobu Sasano; Marco Volante
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.